Dyadic Applied BioSolutions and Proliant Health & Biologicals announced the commercial launch of AlbuFree DX, a recombinant human albumin product produced using Dyadic’s proprietary filamentous fungal expression technology. Under the terms of the agreement, Dyadic will receive a share of profits from Proliant’s commercial sales of recombinant human albumin products.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYAI: